Livestream: The MEKtrix: Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations

Neurofibromatosis type 1 (NF1) presents unique diagnostic and management challenges due to its multisystem involvement and complex neuro-oncologic manifestations. Despite recent advances, including the use of mitogen-activated protein kinase inhibitors, many neurology and neuro-oncology clinicians face difficulties translating novel and emerging clinical trial data into everyday practice, particularly in identifying candidates for mitogen-activated protein kinase inhibitors, managing adverse events, and coordinating multidisciplinary care. Limited experience with NF1 further contributes to gaps in long-term disease monitoring and personalized treatment planning. To close these gaps, clinicians must be equipped with practical, case-based strategies to improve early disease recognition, evidence-based management, and interprofessional collaboration that includes a team-based approach to address both clinical and psychosocial needs in the journey of patients with NF1.

In this CE Concepts livestream symposium, expert faculty will assess neuro-oncologic features of NF1, including tumor types and neurological signs, to support early recognition and guide clinical decision-making; evaluate the use of mitogen-activated protein kinase inhibitors in the management of NF1-associated plexiform neurofibromas in pediatric and adult patients, including team-based care to manage adverse events; and develop evidence-based, interprofessional care plans that reflect current clinical standards and support individualized, longitudinal management.

At the conclusion of this activity, learners will be able to better:

• Assess neuro-oncologic features of neurofibromatosis type 1, including tumor types and neurological signs, to support early recognition and inform clinical decision-making
• Evaluate the use of MEK inhibitors in the management of neurofibromatosis type 1–associated plexiform neurofibromas in pediatric and adult patients, including team-based care to manage adverse events
• Develop evidence-based, interprofessional care plans for pediatric and adult patients with neurofibromatosis type 1 that reflect current clinical standards and support individualized, longitudinal management

This program is supported through an independent educational grant from SpringWorks Therapeutics, Inc.

Neurologists, neuro-oncologists, neurosurgeons, physician associates (PAs), nurse practitioners (NPs), and nurses

It is the policy of CE Concepts, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CE Concepts, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Hirbe reports the following financial relationships:

Advisory Board: Aadi Subsidiary, Inc.

Consultant: Aadi Subsidiary, Inc.; Alexion Pharmaceuticals, Inc.; AstraZeneca; and SpringWorks Therapeutics, Inc.

Grants: Tango

Other financial or material support: Boehringer Ingelheim

Dr. Bornhorst reports the following financial relationships:

Consultant: Alexion Pharmaceuticals, Inc.

Dr. Romo reports the following financial relationships:

Advisory Board: SpringWorks Therapeutics, Inc.

Consultant: Alexion Pharmaceuticals, Inc.

The following individuals have no financial relationships to disclose:

Alaa Bawaneh, MD, PhD (Peer Reviewer)
Andrea Edwards, PA-C (Peer Reviewer)
Susan Perry (Planning Committee)
Nichole Lainhart (Planning Committee)
David Modrak, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CE Concepts, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.